Longevity & AgingOral GLP-1 Pill Hits 11% Weight Loss in Phase 3 Trials
An oral weight loss drug called KAI-7535, developed by Kailera and Hengrui, has shown promising results in two Phase 3 clinical trials. In adults with obesity or overweight, the highest dose produced nearly 11% average body weight reduction over 44 weeks — far outpacing placebo. A separate trial in people with type 2 diabetes showed the drug outperformed an established diabetes medication on blood sugar control. Unlike injectable GLP-1 drugs like semaglutide, KAI-7535 is taken as a pill, which could make it far more accessible. Side effects were mostly mild digestive issues. A global Phase 2 trial is now underway, with results expected in 2027.
